URGN UroGen Pharma Ltd.

UroGen's Zusduri sales surge, Jelmyto revenues and advancing pipeline assets strengthen its shift toward a commercial growth story.

UroGen Pharma has seen its share price move sharply over recent years, which naturally puts a spotlight on whether the current valuation lines up with the sales the business is generating. For anyone looking at the stock today, the core issue is how much of that move can be explained by the company’s revenue base rather than by sentiment alone. Over the past 3 years the stock has delivered a gain of 188.5%, which raises the question of how closely that share price climb tracks the growth in...

For growth investors, Establishment Labs Holdings (NASDAQ:ESTA) presents a compelling equity thesis: a medical aesthetics disruptor transitioning from cash-burning expansion to sustainable, profitable scale. Evaluating the company’s long-term fundamentals, such as its trajectory of multi-year revenue growth, operating cash flow generation, return on invested capital/ROIC, and ultimate free cash flow conversion, reveals a business at […]

UroGen Pharma (NASDAQ:URGN) operates as a specialized oncology and urology therapeutics company anchored by proprietary sustained-release technology platforms. By developing localized drug delivery systems designed to retain therapeutics in targeted tissue sites for extended periods, the company addresses the significant clinical limitations of systemic toxicity and rapid clearance common in traditional cancer treatments. Its underlying […]

Tyra Biosciences and Johnson & Johnson are pursuing their own approaches to treating a common, early-stage form of bladder cancer.

The consensus price target hints at a 27.1% upside potential for Urogen Pharma (URGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Healthcare stocks were mixed Monday afternoon, with the NYSE Healthcare Index up nearly 0.1% and the

Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's find out.

ZUSDURI revenue hit $50.4M, growing 73% QoQ as adoption expands into community practices.

Why UroGen Pharma Stock Is Back in Focus After Q2 2026 Earnings UroGen Pharma (URGN) is back on investors radar after reporting second quarter 2026 results on 5 August, highlighted by higher reported sales and a smaller net loss for both the quarter and first half. The company reported Q2 sales of US$72.46 million with a net loss of US$14.35 million, and first half sales of US$123.42 million with a net loss of US$37.93 million, which may be reshaping sentiment around the stock. See our latest...

UroGen Pharma Ltd. reported past second-quarter 2026 results showing sales of US$72.46 million versus US$24.22 million a year earlier, with net loss narrowing to US$14.35 million from US$49.94 million and basic loss per share from continuing operations improving to US$0.28 from US$1.05. Over the first half of 2026, sales almost tripled to US$123.42 million while the net loss roughly halved to US$37.93 million, suggesting meaningful operating leverage as revenue scales. Next, we’ll examine...

UroGen Pharma Ltd (URGN) reports strong Cysview adoption and pipeline progress, while raising full-year operating expense guidance to support commercial expansion.

Urogen Pharma (NASDAQ:URGN) reported second-quarter 2026 revenue of $72.5 million, up from $24.2 million a year earlier, as the commercial launch of bladder cancer treatment ZUSDURI continued to gain traction. The company recorded a net loss of $14.4 million, or $0.28 per share, compared with a $49.

Urogen Pharma (URGN) delivered earnings and revenue surprises of +26.32% and +16.42%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors showed confidence in healthcare improvements, strong biotech patents, and rising packaging demand.

UroGen Pharma (URGN) has surged nearly 180% over the past year and has strong technical momentum. URGN maintains a 100% “Buy” technical opinion from Barchart. The company’s revenue is projected to more than double this year and grow by 56% next year. Earnings are estimated to rise by 75% and...